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Human B lymphoblastoid cell lines facilitate the growth in vitro ofhuman NK
cells and of T cell clones (1-4), and together with a source of IL-2, have been suc-
cessfullyused to maintain bothNK andT cell clones in culture (1, 2). We have shown
that irradiated B lymphoblastoid cell lines induce proliferation of purified human
NK cells only in synergy with IL-2 (3) . They also facilitate continued proliferation
and enhance the cloning efficiency of purified human NK cells in limiting dilution
assays in the presence of IL-2 without increasing the proportion (>507o) ofNK cells
entering the cell cycle in response to IL-2 (4). During culture of total PBMC with
irradiated B cell lines, NK cells become activated, as shown by increased cytotoxic
activity, by proliferation, and by expression of surface activation antigens such as
class II HLA antigens, transferrin receptors, and IL-2 receptors (5, 6) . In these cul-
tures, a preferential proliferation ofCD16+ CD56(NKH-1)+ CD3 - NK cells is ob-
served (6) : in 10-d cultures, NK cell number is increased 25-fold, whereas T cell
number is increased only 3-fold . Elimination of CD4 + cells or the presence of an
anti-IL-2 antiserum completely preventsNK cell proliferation (6), suggesting that
this probably depends on the production of IL-2 by CD4+ T cells upon allogeneic
stimulation . However, the B cell lines also contribute directly to the proliferation
ofNK cells because in the absence ofB cell lines neither high doses of IL-2 alone
nor stimulation by allogeneicPBMC induce preferential proliferation ofNK cells (6) .
The mechanism bywhich B lymphoblastoid cell lines affect lymphocyte prolifera-
tion is notknown . Studies with bothhuman and murine lymphocytes (7, 8) suggest
a role forimmune interferon(IFN -'Y) inNK andT cell proliferation, although other
studies (4) have shown that IFN-y production is not required. IFN-'Y is produced
in cultures of thymocytes with irradiated B lymphoblastoid cell lines (9) . Low den-
sity murine spleen B cells (10) and certain human B cell lines (Cassatella, M . A .,
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B . Perussia, G. Trinchieri, unpublished observation) directly stimulate purifiedNK
cells to produce IFN-.y . B lymphoblastoid cell lines also produce a variety of other
lymphokines, including IL-1, IL-6, IFN-cx, IFN-(3, lymphotoxin (IT) 1 , and B cell
growth factors (11-14) . However, if soluble factors are involved in the effect ofB cell
lines, those factors are probably either active only at a short range or are produced
only when the B cells are in contact withNK or T cells, since lymphocyte prolifera-
tion requires cell contact or at least contiguity (6, 15) .
In this paperwe report that certainB lymphoblastoid cell lines, constitutively and
after phorbol diester stimulation, produce a novel lymphokine that induces IFN--y
production, augments NK cell-mediated cytotoxicity, and enhances the T cell re-
sponses to the mitogens PHA and phorbol-12,13-dibutyrate (PDBu) when tested on
PBL. This lymphokine, designatedNK cell stimulatory factor (NKSF), was purified
as a 70-kD glycoprotein from the supernatant fluid of the PDBu-induced, EBV
transformed B lymphoblastoid cell line RPMI 8866 . Purified NKSF biological ac-
tivities on NK and T cells can be demonstrated at concentrations as low as 0.1-1 pM .
Materials and Methods
Cell Lines.
￿
The human B lymphoblastoid RPMI 8866 (16) andADP (2), the erythromyeloid
leukemic K562, the Burkitt lymphoma-derived Daudi, and the rhabdomyosarcoma-derived
RDMC cell lines were maintained in culture in RPMI 1640 medium (Flow Laboratories,
Rockville, MD) supplemented with 10% FCS (Flow Laboratories) . All cell lines were free
of mycoplasma contamination on repeated testing .
Preparation of Serumfree Supernatant Fluidfrom Cell Lines.
￿
Cultured cells were washed and
suspended (106 cells/ml) in serum-free RPMI 1640 medium with or without 100 nM PDBu
(Chemical for Cancer Research, Inc ., Eden Prairie, MN) and cultured for 48 h at 37 °C in
a 5% C02 atmosphere . The cell-free supernatant fluids were harvested by filtration through
a 0.2-Am filter (Durapore hydrophilic cartridge filter; Millipore, Bedford, MA) . Tween-20
(0.02%) and PMSF (0 .1 mM) were added to the supernatant fluid of PDBu-induced RPMI
8866 cells to be used for biochemical purification . The fluid was then concentrated 50-fold
under pressure using a Pellicon Cassette System (Millipore) with Pellicon Disc Ultrafilters
(PTGG 00005, Millipore) or a Diaflow hollow-fiber cartridge (HIP 10-20; Amicon Corp .,
Danvers, MA) . Unless otherwise stated, all buffers used for subsequent purification contained
0.02% Tween-20 and 0 .1 mM PMSF.
Peripheral Blood Lymphocytes .
￿
Peripheral blood was obtained by venipuncture from adult
healthy donors using heparin as anticoagulant . PBMC were separated on Ficoll-Hypaque
density gradient (Lymphoprep ; Nygaard and Co., Oslo, Norway) . PBL were prepared from
PBMC after partial depletion of monocytes by adherence to plastic surfaces (45 min, 37°C) .
Cytokines and Cytokine Assays.
￿
Human rIFN-ca (rIFN-A, 2 x 108 U/mg) was kindly pro-
vided by Hoffmann-LaRoche (Nutley, NJ) ; rIL-2 (107 U/mg), by Dr. T. Taguchi, Osaka
University and Takeda Chemical Industry, Inc., Osaka, Japan) ; rIFN-y (107 U/mg), rTNF,
and rLT, by Dr. H . M . Shepard (Genentech Inc ., South San Francisco, CA) ; rIFN-fl, by
Dr. J . S. Price (Cetus Corp ., Emeryville, CA) ; rIL-1 by Dr. P. T Lomedico (Hoffmann-
LaRoche); rIL-1(i and rIL-4 were purchased from Genzyme Co . (Boston, MA) ; rIL-3, rIL-
5, rIL-6, and recombinant granulocyte/macrophage CSF (rGM-CSF) were produced at
Genetics Institute. Inactivating calfanti-IFN-/3 antiserum was provided byDr . J . Vilcek (New
York University, New York, NY); sheep anti-IFN-a antiserum was purchased from Inter-
feron Sciences, Inc . (New Brunswick, NJ) ; goat anti-IL-2, anti-IL-6, anti-LT antisera, and
murine antiTNF and anti-IFN-y mAbs were produced at the Wistar Institute ; rabbit anti-
IL-3 and anti-GM-CSF antisera were produced at Genetics Institute.
IFN antiviral activity was assayed on human diploid fibroblasts and typed using specific
antibodies, as described (17) . IFN-y was measured by RIA as described (18) or with a com-
mercially available kit (Centocor, Malvern, PA). TNF and IT were measured by cytotoxic
assay on murine L cells, and TNF was also tested in radioirnmunoassay as described (18) .KOBAYASHI ET AL.
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IL-1, IL-6, and GM-CSF were measured in biologicalassays as described (19-21). The specificity
of each biologicalassay was confirmed by inhibition ofthe biologicalactivity using neutralizing
antibodies specific for the various cytokines: expression of lymphokine genes in the RPMI
8866 cell line was also confirmed by Northern blotting analysis.
IFN-y Induction Assay.
￿
100 Al ofthe samples to be tested were added in triplicate to PBL
(106 cells/100 id RPMI 1640/10% FCS) in U-bottomed microtiter plates (96-2311; Costar,
Cambridge, MA) and incubated (37 °C, 5% C02) for 18 h. After incubation, 100 pl of cell-
free supernatant was collected from each well and the IFN-y produced was measured by RIA.
This assay was used for standardizationofNKSF activity: 1 U ofNKSF per milliliter is defined
as the amount required to induce one-half of the maximal IFN-y production induced by
optimal concentrations of NKSF
Cell-mediated Cytotoxicity.
￿
PBL were incubated (5 x 106 cells/ml RPMI-10% FCS for 18 h
at 37°C) in the presence or absence of different concentrations of rIFN-a, rIL-2, rIFN--Y,
or a source of NKSF. PBL were then washed and added at different concentrations to 104
target cells in a 3-h 5'Cr-release assay. 1 lytic unit (LU) is the number of lymphocytes medi-
ating one-half of the maximum experimental 5'Cr release (usually 90% of the specific 5'Cr
release measured by detergent lysis) in the 3-h assay period, as calculated using a modified
Von Krogh equation (22) .
Lymphocyte Proliferation.
￿
PBL were cultured (105 cells/200 141 RPMI 1640-10% FCS at
37°C, 5% C02) in triplicate in flat-bottomed 96-well plates for 3 or 6 d in the absence or
presence of 1% PHA-M (Wellcome Research Laboratories, Beckenham, England) or 100 nM
PDBu with or without different concentrations of a source of NKSF. Cultures were pulsed
for 6 h with [3H]TdR (5 liCi/ml; New England Nuclear, Boston, MA) on day 3 or 6; cells
were harvested onto glass fiberfilters and assayed for [3H]TdR incorporation by liquid scin-
tillation counting.
SDS-PAGE.
￿
SDS-PAGE was performed according to the method of Laemmli (23) on 10%
polyacrylamide slab gels (0.75-mm thickness). After electrophoresis, gels were either stained
using silver stainingreagents (Bio-Rad Laboratories, Richmond, CA) or cut into 2-mm slices,
extracted in 0.5 ml RPMI medium for 4 h at 24°C, and assayed for NKSF activity. Apparent
molecular weight was determined using the protein standards: phospholipase B (94 kD), BSA
(67 kD), ovalbumin (43 kD), carbonic anhydrase (30 kD), soybean trypsin inhibitor (20 kD)
and lactalbumin (14 kD). 1251-labeled proteins (chloramineT iodination method, followed
by separation of iodinated protein from free sodium iodide by chromatography on a PD10
column; Pharmacia Fine Chemicals, Piscataway, NJ) were visualized in the dried gels after
exposure to X-ray film.
Anion-Exchange Cartridge Chromatography.
￿
The 50-fold concentrated PDBu-induced RPMI
8866 cell-free supernatant fluid (2 liters) was dialyzed against 0.1 M Tris-HC1 buffer (pH
8.0) and applied at a flow rate of 150 ml/min, to four QAE Zetaprep 250 cartridges (Phar-
macia Fine Chemicals)connected in parallel and previously equilibrated with the same buffer.
The cartridges were washed with three liters of 0.1 M Tris-HC1 buffer (pH 6.8), and NKSF
activity was eluted with 0.5 M NaCl in 0.1 M Tris-HCI buffer (pH 6.8) in five 300-ml fractions.
Lentil Lectin-Sepharose Chromatography.
￿
Pooled NKSFcontaining fractions were applied to
a column (2 .5 x 15 cm) oflentil lectin-Sepharose 4B (Pharmacia Fine Chemicals) that had
been equilibrated with 20 mM Tris-HCI buffer (pH 7.2). The column was washed with five
column volumes of the same buffer and bound material was eluted with three column volumes
of buffer containing 0.2 M ci-methyl-n-mannopyranoside (Sigma Chemical Co., St. Louis,
MO) and 0.5 M NaCl. Approximately half ofthe NKSF activity was bound to the column
and was recovered in the fractions eluted with ce-methyl-o-mannopyranoside.
Hydroxylapatite Chromatography.
￿
The concentrated pool ofNKSF activity bound/eluted from
the lentil lectin-8epharose column was dialyzed against 1 mM potassium phosphate buffer
(pH 6.8) containing 0.1 mM CaC12 and 0.15 M NaCl, and applied to a hydroxylapatite
column (2 x 5 cm, Biogel HT; Bio-Rad Laboratories) previously equilibrated with the same
buffer. The column was washed with five column volumes of equilibration buffer and eluted
with 100 ml of a linear gradient of potassium phosphate buffer (pH 6.8) from 1 to 400 mM
containing 0.15 M NaCl. Fractions (4 ml) were collected and tested for NKSF activity. NKSF
activity eluted in a single peak between -200 and 300 mM potassium phosphate.
Heparin-Sepharose Chromatography.
￿
Eluted NKSF-containing fractions from the Biogel HT83 0 NATURAL KILLER CELL STIMULATORY FACTOR
column were pooled and dialyzed against 20 mM sodium phosphate buffer (pH 7.2) and
applied to a heparin-Sepharose column (1 x 10 cm, Pierce Chemical Co., Rockford, IL).
The column was washed with five column volumes of 20 mM sodium phosphate buffer (pH
7.2) and eluted with 100 ml of a linear gradient from 0 to 1 M NaCl in the same buffer.
Fractions (3 ml) were collected, Essentially all NKSF activity bound to the heparin column
and eluted at -0.6-0.7 M NaCl.
Mono-Q Chromatography.
￿
Pooled fractions from the heparin-Sepharose column were dia-
lyzed against a 20 mM Tris-HCI buffer (pH 6.8) containing 1% ethylene glycol and 1.1 mM
PMSF without Tween-20 and concentrated to 2 ml using a YM 10 membrane in a stirred
cell (Amicon Corp.). The sample was applied to a Mono-Q column (5/5) in a FPLC ap-
paratus (Pharmacia Fine Chemicals) and eluted with a linear gradient of 0-1 M NaCl in
the same buffer (pH 6.8). Fractions (0.5 ml) were collected and tested for NKSF activity.
The activity eluted from the column as a single peak between -220 and 270 mM NaCl. The
same procedure was used to fractionate concentrated crude supernatant fluid from PDBu-
induced RPMI 8866 cells.
Reverse-Phase HPLC (RRHPLQ.
￿
Pooled fractions from the Mono-Q column were applied
to a RP-HPLC column (Aquapore 2.1 x 30 mm column 0711-0056 connected to a 130A Sepa-
ration System; Applied Biosystems, Inc., Foster City, CA) and eluted with a linear gradient
of 0 to 75o7o (vol/vol) acetonitrile containing 0.1°Io trifluoroacetic acid.
Protein Determination.
￿
Protein concentration was determined either using the Bio-Rad
Laboratories protein assay or by measuring absorbanceat 280 nm. BSA was used as a standard.
Results
Identification ofNKSF.
￿
Cells from the EBVtransformed cell line RPMI 8866 were
cultured for 48 h in serum-free medium in the presence of 10' M PDBu. The su-
pernatant fluid from PDBu-induced RPMI 8866 cellscontained various cytokines,
including LT, IL-6, GM-CSF, and IL-1 as detected in biological assays (not shown).
Extensive dialysis to remove contaminant PDBu from the supernatant fluid reduced
the concentration of PDBu to <10-11 M (as determined by scintillation counting
after adding [3H]PDBu to the sample), a level at which PDBu did not affect any
of the bioassays. When added to freshly separated PBL, the supernatant fluid medi-
ated three activities (Table I and Fig. 1) that could not be readily associated with
TABLE I
Production of IFN-y-inducing Activity by Human B Cell Lines
Cell-free supernatant fluids were collected from cell lines cultured for 48 h (106
cells/ml serum-free RPMI 1640 medium) in the presence ( +) or absence ( - )
of 10-7 M PDBu. Dilutions ofextensively dialyzed supernatant fluid were add-
ed to PBL, and IFN--y production was measured after 18 h by RIA.
Cell line PDBu 1/18
IFN-y at supernatant
fluid dilution of:
1/6 1/2
U/ml
RPMI8866 - 2 23 41
RPMI8866 + 40 160 335
ADP - <1 <1 5
ADP + 2 22 38
Raji - <1 <1 <1
Raji + <1 <1 <1d w 0
m
U
n
C N U w N a-
5 10 15 20 25 30 35
Fraction number
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FIGURE 1.
￿
Mono-Q fractionation of
concentrated cell-freesupernatant fluid
from PDBu-induced RPMI 8866 cells.
Fractionseluted at theindicatedNaCl
concentration were dialyzed, sterile
filtered, andtested on PBLfor ability
to:(A)augmentcell-mediatedsponta-
neous cytotoxicity (as tested against
RDMC target cells at an E/Tcell ratio
of 25:1); (B) enhance proliferation in
thepresence ofPHA(6-d culture); (C)
induce IFN--y production.
any of the known cytokines present in the supernatant fluid: (a) it induced IFN-,y
production; (b)it augmented spontaneouscytotoxic activity against avarietyoftarget
cell lines; (c) it enhanced proliferation ofPBL in response toPHA orPDBu. IFN-.y-
inducing activity was also detected in the supernatant ofunstimulated RPMI 8866
cells, but at levels ti10-fold lowerthan in supernatants ofPDBu-induced cells (Table
I). Asimilar, but lower activity, was detected in the supernatant fluid ofthe EBV
transformed cell lineADP (Table I), whereas no activity was detected in the super-
natant fluids ofother human cell lines tested, including four B, six myeloid, and
five T cell lines, regardless of PDBu induction (Table I and not shown).
Previously characterized lymphokines, either present in the supernatant fluid or
not, were analyzed for ability to mediate the three activities on PBL. Because this
analysis consistently gave negative results, those data are only summarized here.
Recombinant IL-lca, IL-10, IL-3, IL-4, IL-5, IL-6, IFN-a, IFN-0, GM-CSF, TNF,
and LT, tested in a wide range of concentrations, did not induce production of
significant amounts ofIFN-y by PBL. rIL-2 consistently induced IFN-y produc-
tion, but the level of IFN-y induced by doses ofrIL-2 as high as 1000 U/ml was
always lowerthanthat inducedbysupernatantfluids diluted 1:2 from PDBu-stimulated
RPMI 8866 cells. Anti-IL-2, IL-3, IL-6, TNF, LT, GM-CSF, IFN-a, and IFN-/3
neutralizingantibodies did not inhibit the ability ofRPMI 8866 supernatant to in-832
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duce IFN-,y production. The supernatant fluid ofPDBu-stimulatedRPMI 8866 cells
contains -5 ng/ml of LT (24). LT, purified to homogeneity from this supernatant,
has no IFN--y-inducing, NK cell-augmenting, or comitogenic activity when tested
on PBL (24). Supernatant fluids from PDBu-induced RPMI 8866 cells also con-
tained -50 antiviral units ofIFN, which was inhibited partiallyby antiserum against
IFN-a or IFN-/3 and completely by acombination ofthe two. Such an IFN concen-
tration is sufficient to induce a modest increase in NK cell-mediated cytotoxicity
(25). However, the two anti-IFN antisera didnot suppress the abilityofRPMI 8866
supernatant to enhance NK cell-mediated cytotoxicity.
Serum-free medium from PDBu-induced RPMI 8866 cells was concentrated by
membrane filtration under pressure using capillary tubings or filters with a 10-kD
exclusion limit. The concentrated material was fractionated by gel filtration on
Sephadex G100, by ion-exchange chromatography on a Mono Qcolumn, orby hy-
drophobic chromatography on a phenyl-Sepharose column. Fractions were tested
for biological activity on PBL. Fig. 1 illustrates the results obtained with the frac-
tions fromtheMono-Qcolumn. With this column, and also withthe other two (not
shown), the IFN-,y-inducing activity, the NK cell-enhancing activity, andthecomito-
genic activity eluted in the same fractions, suggesting that the three activities were
mediated by a single anionic protein of-70 kD. This protein, designated NKSF,
was further purified on the basis of its IFN--y-inducing activity.
Determination ofNKSFMolecularMoss bySDS-PAGE.
￿
Concentrated supernatant from
PDBu-induced RPMI 8866 cells was separated by SDS-PAGE under nonreducing
and reducing conditions (Fig. 2). The NKSF activity was recovered from the un-
s4 -
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0
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FIGURE 2.
￿
Size determination ofNKSF
in RPMI 8866-conditioned medium.
NKSF was incubated with sample buffer
at 37°C for30 minandsubjectedto SDS-
PAGE (10% gel) under (A) nonreducing
and (B) reducing conditions. After elec-
trophoresis, the gel was cut into 2-mm
slices and extracted with 0.5 ml ofRPMI
1640 medium at 24°C for 4 h. Each ex-
tract was sterile filtered and assayed for
NKSF activity, expressedas U/ml ofIFN-
.y induced in the PBL cultures.KOBAYASHI ET AL.
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reduced gel as a single species with apparent molecularmass of70 kD. Thus, most
NKSF activity produced by RPMI 8866 cells appears to reside in a 70-kD protein.
However, because not all cytokines can be recovered from gels in active form after
SDS treatment, the possibilityremainsthatother SDS-sensitive moleculeswith NKSF
activity areproduced by RPMI 8866 cells but were not detected in this experiment.
Purification of NKSF.
￿
The low level of NKSF activity in the serum-free condi-
tioned medium (10 U/ml) necessitated the purification ofthe NKSF activity from
large amounts (192 liters)ofconditioned medium inorder to obtain sufficient mate-
rial fordetailed biochemical andbiological analysis. The purification scheme, sum-
marized in Table II, included the following sequential steps: filtration through a
QAE-Zetaprep cartridgethat selectively binds anionic proteins; affinity chromatog-
raphy on alentil lectin-Sepharose column; hydroxylapatite column chromatography
oftheactivity recovered inthe bound fraction fromthe lentil lectin column; affinity
chromatography on heparin-Sepharose; anion-exchange chromatography on a Mono-
Qresin column; and RP chromatography on an Aquapore column.
Asubstantial amount ofNKSFactivity waslost during the early steps ofthe puri-
fication protocol. ApproximatelyhalfofNKSF activity bound tolentil lectin-Sepha-
rose, indicating that the NKSF molecule is, at least in part, glycosylated. Specific
activity of NKSF recovered in the lectin-unbound fraction was much lower than
that oftheboundfraction. Forpractical purposespurification ofonly thelectin-bound
fractionwaspursued, althoughin thiswaycharacterization ofan NKSFspecies with
lower or no glycosilation might have been missed. Essentially all of the NKSF ac-
tivity recovered in the bound fractions from the lentil lectin and hydroxylapatite
columns bound to heparin-Sepharose with intermediate to high affinity. NKSF was
released from the heparin-Sepharose column at 0.6-0.7 M NaCl. Recovery oftotal
NKSF activity increased substantiallybothafterthelentil lectin and heparin-Sepharose
fractionation steps: in the former case, the yield of activity in the bound fraction
was 1007o despite the fact that half ofthe recovered activity was found in the un-
bound fraction; in the latter case the yield of activity was 4507o with a 16-fold
purification. Possibly, inhibitory substances were concentrated alongwith theNKSF
activity during the earlystepsofpurification butwereremoved during thelater steps.
TABLE II
Purification of NKSF
Purification steps
Total
protein
Total
activity
Specific
activity Yield Purification
Mg U x 10-5 U/mg x 10-3 % fold
1 . Cell supernatant (192 liters) 4,350 20 0.45 100 1
2. Concentrated supernatant (4 liters) 4,200 9.6 0.23 48 <1
3. QAE-Zetaprep cartridge 670 1 .4 0.21 7 <1
4. Lentil lectin-Sepharose 31.5 1 .5 4.70 8 10
5. Hydroxylapatite 10.0 0.94 9.40 5 20
6. Heparin-Sepharose 3.17 4.5 140 22 320
7. Mono-Q-FPLC 0.072 3.0 4,160 15 9,200
8. RP-HPLC 0.018 0.03 167 0.15 371834
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FIGURE 3 .
￿
Analysis ofthe Mono-Qfractionation (Step 7) oftheNKSF purification . (A) Profiles
ofNKSF activity (") in units IFN-.y induced per milliliter and protein concentration (-) (A2eo)
eluted from theMono-Qcolumn with the indicated (---) salt gradient . (B) Fractions20-25from
theMono-Qcolumn were analyzed by SDS-PAGE (10% gel) . The relative positions ofmolecular
mass reference proteins are indicated .
NKSF activity eluted as a single peak from a Mono-Qcolumn with0.25M NaCl
(Fig . 3) . TheMono-Q purification step resulted in a 30-fold purification of NKSF
with 70% recovery of total activity (Table II) . Recovery of biologic activity after
theMono-Qstep was 15% and the specific activity oftheNKSF protein at this point
was 4.2 x 106 U/mg. This purified NKSF did not contain significant amounts of
IL-1, IL-6, TNF, LT, GM-CSF, or IFN, as determined in biological assays (not shown).
Fig. 3 shows the SDS-PAGE analysis under nonreducing conditions of each of
theNKSFcontaining and several adjacent fractions from the Mono-Q-FPLC frac-
tionation (Step 7) . A prominent species with apparent molecularmass of 70 kD was
present in each ofthe NKSFcontaining fractions but absent from the adjacent frac-
tions. The size estimate for this protein species is in agreement with that of the ac-
tivity eluted from theSDS gel shownin Fig . 2 . Furthermore, the 70-kD species eluted
from an unstained gel was active in the IFN-y induction assay (not shown) . These
results are consistent with the identification of the 70-kD species visible in the gel
shown in Fig . 3 as NKSF. Assuming a molecular mass of 70 kD for NKSF, and
based on the specific activity of the Step 7 material, we calculated that a final con-
centration of 3 .5 pM NKSF yielded half of the maximal response in the IFN-y-
induction assay (1 U NKSF).
The 70-kDproteinwasfurther separatedfrom contaminating proteins in theprep-
aration using RP-HPLC (Fig. 4) . NKSF was highly sensitive to the solvents used
in theRP fractionation andexposure to them resulted in profound reduction of bio-
logic activity (not shown) . The presence of the 70-kD species in the fractions from
the RP-HPLC column correlated well with the presence of NKSF activity in the
same fractions, although the total recovery of activity' from the column was onlyKOBAYASHI ET AL .
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FIGURE 4.
￿
Analysis oftheRP-HPLC fractionation (Step 8) oftheNKSF purification. (A) Profiles
ofNKSF activity (O)and protein concentration (A214, ---) eluted from the RP-HPLC column
with the indicated gradient of acetonitrile were as shown . (B) Fractions35-43 from theRP-HPLC
fractionation were analyzed by SDS-PAGE in parallel with the indicated reference proteins .
1% (Fig . 4) . Therefore, theRP-HPLC step resulted in the inactivation of 99% of
theNKSF activity but yielded an estimated 90% ofNKSF protein (Fig. 4) . Thus,
biologic studieswere performed using NKSF from the penultimate purification step
(Step 7), and the most highly purified, but largely inactive material from the final
RP column (Step 8) was used for biochemical characterization . Final recovery of
protein at this step was 18 hg, obtained from 192 liters of supernatant fluid.
SDS-PAGE Analysis ofthe PurifiedNKSF Protein.
￿
To further analyze the structure
of the NKSF protein, the Step 7 material was labeled with 1251 and subjected to
SDS-PAGE under nonreducing conditions . The 70-kD species was eluted from the
gel and fractionated on a reducing gel . As illustrated in Fig. 5, reduction of the gel-
purified, 1251-labeled NKSF resulted in thedisappearance of the 70-kD species and
the appearance of two new polypeptides with apparent molecular masses of 40 and
35-kD. Thus, NKSF appears to have a heterodimeric structure comprising two
disulfide-linked monomers with masses of 40 and 35 kD, respectively. However, the836 NATURAL KILLER CELL STIMULATORY FACTOR
FIGURE 5 .
￿
SDS-PAGE analysis of the 70-kD NKSF protein after reduc-
tion. (A) Radioiodinated (Step 7)NKSF subjected to SDS-PAGE under non-
reducing conditions. (B) The 70-kD species eluted from gel A was reana-
lyzed by SDS-PAGE after reduction with 2-ME. The relative mobilities of
reference proteins in the second gel are indicated .
inactivation ofNKSFupon reduction has prevented the ultimate demonstration tha
both polypeptides are required to yield the active NKSF species .
IFN- ,y Induction by PurifiedNKSF .
￿
Purified NKSF (Step 7) induces INF'Y produc-
tion by human PBL . The levels of IFN-,y produced using PBL preparations from
different donors were variable . In the experiment depicted in Fig . 6, 18-h treatment
ofPBL with 2 U/ml NKSF (7 pM) yielded up to 300 U/ml IFN-y, whereas 1,000
U/ml of IL-2 (N20 nM) yielded only 200 U/ml IFN-y . When tested in combina-
tion, the two factors acted synergistically . With optimal concentrations ofbothNKSF
and IL-2, IFN- ,y levels higher than 1,000 U/ml were observed with PBL of most
NKSF, U/ml
FIGURE 6.
￿
Induction of IFN-,y pro-
duction byNKSF and IL-2 . PBLwere
incubated(18 h, 37°C) in the presence
ofthe indicated concentrations ofNKSF
and the following concentrations of
rIL-2 : (") none ; (O) 10 U/ml;(A)40
U/ml; (A) 100 U/ml; (0) 400 U/ml ;
(p) 1,000 U/ml . Supernatant fluids
were collected and tested for IFN--y
content by RIA. Theisobologram in
the inset shows the concentrations of
the twolymphokines needed to induce
150U/ml IFN- ,ywhen used in combi-
nation .donors. The combination of 10 U/ml IL-2 (200 pM) and 0.4 U/ml NKSF (N1.5
pM), concentrations thatby themselves were almost ineffectivein the assay, induced
production ofas much as 500 U/ml IFN-y by PBL. The interaction between these
two factors was evaluatedbyisobologram analysisinwhich the concentration ofIL-
2 required to induce production of 150 U/ml IFN-y was plotted as a function of
NKSFconcentration(Fig. 6, inset). Theexperimental results strikingly deviated from
the expected results for an additive effect, indicating strong synergistic interaction
between the two cytokines.
EnhancementofPBL-mediatedSpontaneous Cytotoxicity byPurifiedNKSF.
￿
Spontaneous
cytotoxicity mediated by PBL against three target cell lines was augmented by cul-
turing PBL in thepresence ofNKSF for 18 h (Fig. 7). This enhancement ofsponta-
neous cytotoxicity was dose dependent over the range of 0.08-4 U/ml of NKSF
(0.29-14.4 pM). The observed enhancement was most pronounced using as target
Daudi cells, which are largely resistant to killing by unstimulated NK cells. The
effector cells mediating cytotoxicity were CD16+, CD3-, CD5- NK cells, as demon-
strated by cell separation experiments using specific mAbs (not shown) .
NKSF appears to be the most potent ofthe known NK cell-activating cytokines
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FIGURE 7. Enhancement of PBL-mediated
spontaneous cytotoxicity by NKSF. PBLwere in-
cubated (18 h, 37°C) in the presence of (")
medium only; (A) 0.08 U/ml NKSF; (") 0.4
U/ml NKSF; (/) 2 U/ml NKSF PBL were
washed and used as effector cells in a 3-h "Cr-
release assay against SICr-labeled Daudi,
RDMC, and K562 target cells, as indicated.838
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￿
Enhancement of PBL-mediated spontaneous cytotoxicity on RDMC target cells.
PBLwere incubated (18 h, 37°C)in the presence of the indicated concentrations of(0) NKSF;
/), rIL-2; (A)rIFN-a; (") rIFN-,y. PBLwere then washed andused as effector cellsin a3-h
ICr-release assay. The discontinuous line indicatesthecytotoxicity mediated by PBL incubated
in medium alone.
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FIGURE 9.
￿
Effect of NKSF on PBL
proliferation induced by PHA (A) or
PDBu (B). PBL were cultured in the
presence of the indicated concentra-
tions of NKSF and (O, O) medium;
(", ") 1% PHA(A)or 100nM PDBu
(B); [3H]TdR uptake was measured
at: (O, ") day3; (p, /) day 6. Ver-
tical bars indicate 1 SD of triplicates.KOBAYASHI ET AL.
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tested (Fig. 8). A significant enhancement of PBL-mediated cytotoxicity was ob-
served in PBL treated for 18 h with concentrations of NKSF between 0.10 and 10
U/ml (0.36-36 pM). The generation ofsimilar levels of cytotoxicity required con-
centrations of IL-2 >50 U/ml (>1 nM) or of either IFN-a or IFN-y >1,000 U/ml
(>100 PM).
Comitogenic Activity ofPurifiedNKSF .
￿
PBL were cultured in thepresenceofpurified
NKSF (Step 7) alone or in the presence of NKSF and either PHA or PDBu (Fig.
9). NKSF alone did not induce detectable levels ofproliferation as measured by in-
corporation of [3H]TdR on either day 3 or 6 of culture. In the presence of either
PHA or PDBu, NKSF induced a significant dose-dependent proliferative response
detectable on day 6 in PHA-stimulated culture and on both days 3 and 6 in the
PDBu-stimulated cultures. The half-maximal activity ofNKSF in the comitogenic
assay was observed at NKSF concentrations (ti0.35 pM) N10-fold lowerthan those
effective in the INFy-inducing assay (Figs. 6 and 9).
Discussion
We have identified and purified from the conditioned medium of an EBV
transformed B cell line a novel 70-kD glycoprotein that when added to cultures of
restingPBLs, induces production ofIFN-y, augments NK cell-mediated cytotox-
icity, and enhances proliferation induced by mitogenic lectins and phorbol diesters.
Theidentification ofthis 70-kD protein asthe active component in these assays rests
in: (a) the elution of biologic activity from SDS gels with an apparent molecular
mass of70kD; (b) the co-purification ofthis protein with thesethree biologic activi-
ties through a9,200-fold purification; and(c)thehigh specific activity ofthe purified
protein with half-maximal activity in the IFN-y-induction assay at 3.5 pM. Upon
reduction, the most highly purified preparation of 70-kD NKSF yielded two poly-
peptides with approximate molecular masses of 40 and 35 kD, suggesting that the
native molecule is a disulfide-linked heterodimer. The purification results strongly
suggest that a single major 70-kD protein is present in the purified NKSF prepara-
tion and that this protein mediatesthe threebiological activities. However, because
even the most purified NKSF preparations still contain traces of other peptides, it
cannot be excluded that the biological activities reside in different minor compo-
nents of -70 kD present in the preparations or that the two bands in the reduced
preparation originate from different 70-kD components comigrating at the same
position in nonreducing gels. Only amino acid sequencing and molecular cloning
efforts, which arenowinprogress, will allowus toexclude theseunlikely possibilities.
The biologic activities of NKSF and its biochemical characteristics distinguish
it from other known cytokines. A role for other lymphokines produced by RPMI
8866 cells inNKSF biologicactivitiesis excludedbecausethelymphokinesidentified
in the supernatant fluid were eliminated during purification. Moreover, antibodies
against the identified lymphokines or others, not detectable in the NKSF prepara-
tion but that might be expected to mediate similar biologic effects, do not inhibit
NKSF activities. Finally, the high specific activity ofpurified NKSF argues against
the possibilityoflow level contaminationofthepreparations withotherlymphokines.
Relatively few ofthe known cytokines induce IFN-y production by resting PBL.
Reem et al. (9) reported that B lymphoblastoid cell lines, different from the one
used in the present study, and their supernatant fluids induce IFN-y production840
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by human thymocytes, but those authors did not further characterize this activity.
Amongthe cytokines that we have tested, only IL-2 consistently induces significant
levels ofIFN-y production by PBL (26). The strong synergism between NKSF and
rIL-2 in inducing IFN-y production and the inability of anti-IL-2 antibodies to
significantlyinhibittheeffect ofNKSF exclude that IL-2 is responsiblefor theNKSF
activity. The synergistic effect ofthese twocytokines also suggests that IL-2 and NKSF
induce IFN-y production by PBL acting through different receptors and probably
different intracellular signal transduction pathways. Both rIL-1 (27) and rIL-6 (not
shown) occasionally induced low level IFN-y production in our assay system but
failed to synergize with IL-2. IL-6 hsabeen shown in other systems to induce IL-2
production, whichmight accountfor its IFN-y-inducing activity (28). Recently, IFN-
y-inducing activity has also been described in theconditioned medium from galac-
tose oxidase-treated monocytes (29, 30). The biologic activities of this factor are
in part similar to those of NKSF. However, the distinct biochemical properties of
the 70-kD NKSF clearlydistinguish it from the monocyte-derived lymphocyte stimu-
lator. Moreover, the latter factor does not synergize with IL-2, but rather appears
to induce IFN-y indirectly, via induction of IL-2 (29).
The culture system that wehave used to study the induction ofIFN-y production
by unfractionated lymphocytes is acomplexbiologic system with many possible di-
rect and indirect interactions between different cells and cytokines (26, 27). The
production of IFN-y in response to IL-2 requires HLA-DR' accessory cells (27,
and our unpublished results) and is due largely to NK cells (26). Preliminary ex-
perimentswith NKSFindicate that the action ofthis cytokine also requires an HLA-
DR+ accessory cell population and that both NK and T cells might produce IFN-
y in response to NKSF, although the relative contribution of the two cell types re-
mains to be established.
Severallymphokines enhance NK cell-mediatedcytotoxicity. Among thoseidentified
in RPMI 8866 supernatant fluid, IFN (25) and, to a much lower extent, LT (31)
are known to be NK cell activators. However, the absence ofthese lymphokines in
purified NKSFpreparations and the inabilityofspecific inactivating antiseratoblock
the NK cell-enhancing effect ofboth crude and purified NKSF preparations ex-
clude a role for either IFN or LT in this effect of NKSF IL-2 is also a potent acti-
vator of NK cell-mediated cytotoxicity (26, 32). Upon addition ofIL-2 to cultures
of resting PBL, a dose-dependent increase in spontaneous NK cytotoxicity is ob-
served within afew hours; this increase both precedes and is independent ofIFN-y
production in the same cultures (26). NKSF wasable toenhance spontaneous cyto-
toxicity of resting PBL at molar concentrations at least two orders of magnitude
lower than the concentrations ofIFN or IL-2 required to achieve similar responses.
Preliminary observations suggest that the augmenting effect of NKSF on NK
cell-mediated cytotoxicity, as in thecase ofIL-2, is mostly independent oftheIFN-
y produced in the culture. The relatively high concentrations of IL-2 required for
both IFN-y production by PBL and augmentation ofNK cell-mediated cytotox-
icityis explainedbythefindingthat IL-2 actson restingPBLthroughthe intermediate-
affinity p70 chain of the IL-2 receptor and not through the high-affinity receptor
that includes the p55 Tac chain (26, 33-35). The ability of NKSF to mediate the
same biologic activities at amuch lower concentrationthan IL-2 suggests the possi-KOBAYASHI ET AL.
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bility ofa high-affinity NKSF receptor expressed on resting NK cells and possibly
on all resting PBL.
NKSF alone is not mitogenic for resting PBL and does not synergize with rIL-2
ininducing proliferation. However, NKSF at very low molecularconcentrationshas
a potent comitogenic effect with two T cell mitogens, PHA and PDBu. The effect
ofNKSF together with PHA is not demonstrable during the peak ofthe PHA re-
sponse, but becomes significant at later times when PBL proliferation in cultures
withPHA alone usuallydeclines; in the presenceofboth PHA and NKSF, prolifera-
tioncontinues to increase foratleast 6 d. Theeffect ofNKSFadded at the beginning
ofthe culture is therefore observed after several days. By contrast, the comitogenic
effect ofNKSF with PDBu is clearly observed at both 3 and 6 d ofculture. Prelimi-
nary characterization ofthe cells proliferating in response to PHA or PDBu, with
or without NKSF, showed that virtually all of them are Tcells. Because PHA and
PDBu are mitogenic for T cells but not for NK cells, this finding suggests that the
cellular specificity of the induced proliferation is determined by the specificity of
the mitogens used. The comitogenic effect on T cells also confirms that, as in the
case ofinduction of IFN-y production, NKSF acts not only on NK cells, but also
has important regulatory functions on Tlymphocytes. Further analyses should re-
vealwhetherNKSF is acting directly as a Tcell growth factor orwhether its growth-
promotingeffects are mediated by inductionofsecondarygrowth factor production
in culture.
Lymphocyte proliferation in different systems has been shown to require IFN-,y
(7, 8) and IFN-y might play a role in the effect of NKSF on proliferation. By in-
ducing IFN--y, and possibly other lymphokines, NKSF might expand the range of
its possible biologiceffectsboth in vitroandinvivo. Because NKSFhas been identified
at this time only as a product of in vitro established virus-transformed B cell lines,
one can only speculate on its possible physiological role in the interaction ofnormal
B cells with T and NK cells. In the mouse, activated spleen B cells induce NK cells
toproduceIFN-y, which inhibitsthe polyclonal Ig productioninduced by LPS (10).
In nude mice IFN-yproduction by NK cells is anecessary requirement for a B cell
response tothymus-independent antigens (36). Similarly, NK cells, probablythrough
IFN-y production, are necessary for recovery of B cell function ofpatients in the
early times after bonemarrow transplantation (37). Induction ofIFN-y production
is therefore an important aspect ofthe functional interaction in vivo between acti-
vated B cells and bothNK and Tlymphocytes. Thepossibilitythenarises that normal
B cells produce NKSF or other IFN-y-inducing factors.
Although NKSF has potent effects on NK cell cytotoxicity and on lymphocyte
proliferation, it does not account completely for the various effects mediated by ir-
radiated B lymphoblastoid cell lines on PBL cultures. Furthermore, we could not
demonstrate NKSF production by the Daudi cell line, which is a powerful inducer
of preferential NK cell proliferation in PBMC cultures (6). However, Daudi and
other cell lines can induce NK cells to produce IFN-y when directly added to the
culture, suggesting the possibility that NKSF is produced by these cell lines at a
low concentration acting only on contiguous cells or that it is expressed in a non-
secreted membane-bound form, as shown for othercytokines such as IL-1 or TNF.
Although NKSF alone doesnot account for the whole spectrum ofstimulatory and84.2
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accessory functionsofB cell lines addedto PBL cultures, it mayrepresent an impor-
tant and possibly necessary mediator for some of these functions.
IL-2 can activate different lymphocyte populations to kill tumorcellsboth inanimals
andinhumans(26, 32, 38-40). Avarietyoftherapeutic approachesusing IL-2 have
been attempted, including treatment of patients with IL-2-activated lymphocytes
obtained from ex vivo cultures of the patient's own lymphocytes in the presence of
high concentrations of IL-2 (39). These approaches have occasionally shown some
promise, but substantial improvement isclearly necessarybefore theyhavea significant
impact on cancer therapy. The ability ofNKSF to augmentlymphocyte cytotoxicity,
to induce IFN-yproduction, and to enhance proliferation ofresting PBL atconcen-
trations much lower than those at which IL-2 is effective, as well as the synergistic
effect with IL-2 in some ofthese functions, might make this factor a promising can-
didate for clinical use, alone or in combination with other cytokines, in the therapy
of cancer and other diseases.
Summary
We have identified and purified a novelcytokine, NKcell stimulatoryfactor (NKSF),
from the cell-free supernatant fluidofthephorboldiester-induced EBVtransformed
human B lymphoblastoid cell line RPMI 8866. NKSF activity ismostly associated
to a 70-kD anionic glycoprotein. The purified 70-kD protein, isolated from an SDS-
PAGE gel, yields upon reduction two small species ofmolecular masses of40 and
35 kD, suggesting that this cytokine is a heterodimer. When added to human PBL,
purified NKSF preparations induce IFN-y production and synergize with rIL-2 in
this activity, augmentthe NK cell-mediated cytotoxicityofPBLpreparations against
both NK-sensitive and NK-resistant target cell lines, andenhance the mitogenic re-
sponse of T cells to mitogenic lectins and phorbol diesters. The three activities re-
main associated through different purification steps resulting in a 9,200-fold
purification, and purified NKSF mediates the three biological activities at concen-
trations in the range of0.1-10 pM. These data strongly suggest that the same mole-
cule mediates these three activities, although the presence oftraces ofcontaminant
peptides even in the most purified NKSF preparations does not allow us to exclude
the possibility that distinct biologically active moleculeshave been co-purified. The
absence of other known cytokines in the purified NKSF preparations, the unusual
molecular conformation of NKSF, the high specific activity ofthe purified protein,
and the spectrum of biological activities distinguish NKSF from other previously
described cytokines.
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for assistance in preparing the manuscript; and M. Hoffman for editing.
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